Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Kimberly H. Johnson acquired 13 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Summary

• Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 13 shares of common stock on April 15, 2024.
• The shares were acquired at a price of $750.77 per share.
• This acquisition was made through the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Johnson's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director alignment with the company's long-term success. There is no indication of any negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among large publicly traded companies, such as those in the pharmaceutical sector like Pfizer (PFE) and Johnson & Johnson (JNJ).
• These plans are often used to align the interests of directors with those of shareholders by providing long-term equity incentives.
• The specific terms of deferral and vesting may vary, but the general concept is consistent across the industry.

Stakeholder Impact

• The acquisition of shares by a director can be viewed positively by shareholders as it indicates confidence in the company's future performance.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, SEC Form 4, LLY, Kimberly H. Johnson